Patents by Inventor Scott D. Larsen

Scott D. Larsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190308947
    Abstract: Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Application
    Filed: April 5, 2019
    Publication date: October 10, 2019
    Inventors: Scott D. Larsen, Richard Neubig, Kim Hutchings, Dylan Kahl, Erika Mathes Lisabeth
  • Publication number: 20190255055
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a thiopyrimidinone structure which function as inhibitors of ALDH protein, and their use as therapeutics for the treatment of cancer and other diseases.
    Type: Application
    Filed: June 20, 2017
    Publication date: August 22, 2019
    Inventors: Scott D. Larsen, Brandt C. Huddle, Kun Yang, Ronald Buckanovich, Thomas Hurley
  • Patent number: 10329283
    Abstract: Disclosed herein are novel GRK inhibitors and methods for their use in treating or preventing heart disease, such as cardiac failure, cardiac hypertrophy, and hypertension. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein the substituents are as described.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: June 25, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Scott D. Larsen, John J. G. Tesmer, Helen Waldschmidt, Kristoff Homan, Michael William Wilson
  • Patent number: 10202340
    Abstract: Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: February 12, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Scott D. Larsen, Akira Abe, Liming Shu, Michael William Wilson, Richard F. Keep, Duxin Sun, James A. Shayman
  • Patent number: 10023564
    Abstract: Disclosed herein are novel GRK2 inhibitors and methods for their use in treating or preventing heart disease, such as cardiac failure, cardiac hypertrophy, and hypertension. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: wherein the substituents are as described.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: July 17, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Scott D. Larsen, Kristoff Homan, Helen Waldschmidt, John J. G. Tesmer
  • Publication number: 20180186779
    Abstract: Disclosed herein are novel GRK inhibitors and methods for their use in treating or preventing heart disease, such as cardiac failure, cardiac hypertrophy, and hypertension. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein the substituents are as described.
    Type: Application
    Filed: June 27, 2016
    Publication date: July 5, 2018
    Inventors: Scott D. Larsen, John J.G. Tesmer, Helen Waldschmidt, Kristoff Homan, Michael William Wilson
  • Publication number: 20180022697
    Abstract: Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 25, 2018
    Inventors: Scott D. Larsen, Akira Abe, Liming Shu, Michael William Wilson, Richard F. Keep, Duxin Sun, James A. Shayman
  • Publication number: 20170240538
    Abstract: Disclosed herein are novel GRK2 inhibitors and methods for their use in treating or preventing heart disease, such as cardiac failure, cardiac hypertrophy, and hypertension. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: wherein the substituents are as described.
    Type: Application
    Filed: August 10, 2015
    Publication date: August 24, 2017
    Inventors: Scott D. Larsen, Kristoff Homan, Helen Waldschmidt, John J.G. Tesmer
  • Patent number: 9598441
    Abstract: The invention provides compounds of formula I: and salts thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating cancer using compounds of formula I.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: March 21, 2017
    Assignees: Wayne State University, Regents of the University of Michigan, Department of Veteran Affairs
    Inventors: Arun K. Rishi, Scott D. Larsen
  • Patent number: 9562012
    Abstract: The present invention relates to hydroxamate compounds and pharmaceutical compositions that are useful for treating and/or preventing metabolic inflammation mediated diseases such as diabetes, obesity, hypertension, dyslipidemia, a neurodegenerative disorder (e.g., Alzheimer's disease, Parkinson's disease, or Huntington's disease), or any combination thereof. Moreover, the present invention also provides methods of treatment for these diseases or disorders.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: February 7, 2017
    Assignee: Metabolic Solutions Development Company, LLC
    Inventors: Steven P. Tanis, Scott D. Larsen, Gerald D. Artman, III, Timothy Parker
  • Patent number: 9504688
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections (e.g., biofilms).
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: November 29, 2016
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, THE CURATORS OF THE UNIVERSITY OF MISSOURI
    Inventors: David Ginsburg, Scott D. Larsen, Bryan Yestrepsky, Hongmin Sun
  • Patent number: 9468632
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against cancer stem cells.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: October 18, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Ronald Buckanovich, Scott D. Larsen, Kun Yang
  • Publication number: 20160152570
    Abstract: The present invention relates to hydroxamate compounds and pharmaceutical compositions that are useful for treating and/or preventing metabolic inflammation mediated diseases such as diabetes, obesity, hypertension, dyslipidemia, a neurodegenerative disorder (e.g., Alzheimer's disease, Parkinson's disease, or Huntington's disease), or any combination thereof. Moreover, the present invention also provides methods of treatment for these diseases or disorders.
    Type: Application
    Filed: July 21, 2014
    Publication date: June 2, 2016
    Inventors: Steven P. Tanis, Scott D. Larsen, Gerald D. Artman, III, Timothy Parker
  • Publication number: 20160145251
    Abstract: Disclosed herein are inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, or both myocardin-related transcription factor and serum response factor (“MRTF/SRF”), and methods for their use in treating or preventing cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 26, 2016
    Inventors: Scott D. Larsen, Richard Neubig, Andrew Haak, Kim Hutchings, Walajapet Rajeswaran
  • Publication number: 20150297577
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against cancer stem cells.
    Type: Application
    Filed: November 26, 2013
    Publication date: October 22, 2015
    Inventors: Ronald Buckanovich, Scott D. Larsen, Kun Yang
  • Publication number: 20150250769
    Abstract: The present disclosure relates to methods, compositions, and kits for the inhibition of signaling by members of the Rho GTPase family. Specifically, the disclosure relates to methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signaling and action of the transcription co-factors MRTF-A and/or MRTF-B. The disclosure finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis and fibrosis), Rho-mediated biological conditions, and in cell signaling research.
    Type: Application
    Filed: March 9, 2015
    Publication date: September 10, 2015
    Inventors: Scott D. Larsen, Jessica L. Bell, Richard Neubig, Kim Hutchings
  • Patent number: 9126959
    Abstract: The present invention relates to novel salts of thiazolidinediones and other pharmaceutical agents that are useful for treating and/or preventing metabolic diseases (e.g., diabetes, or neurodegenerative diseases (e.g., Alzheimer's Disease).
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: September 8, 2015
    Assignee: Metabolic Solutions Development Company, LLC
    Inventors: Gerard R. Colca, Steven P. Tanis, Scott D. Larsen
  • Publication number: 20150132352
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections (e.g., biofilms).
    Type: Application
    Filed: May 2, 2013
    Publication date: May 14, 2015
    Inventors: Hongmin Sun, Bryan Yestrepsky, David Ginsburg, Scott D. Larsen
  • Publication number: 20150051406
    Abstract: The present invention relates to novel salts of thiazolidinediones and other pharmaceutical agents that are useful for treating and/or preventing metabolic diseases (e.g., diabetes, or neurodegenerative diseases (e.g., Alzheimer's Disease).
    Type: Application
    Filed: October 30, 2014
    Publication date: February 19, 2015
    Inventors: Gerard R. Colca, Steven P. Tanis, Scott D. Larsen
  • Patent number: 8946435
    Abstract: The present invention provides novel methods for synthesizing PPAR? sparing compounds, e.g., thiazolidinediones, that are useful for preventing and/or treating metabolic disorders such as diabetes, obesity, hypertension, and inflammatory diseases.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: February 3, 2015
    Assignee: Metabolic Solutions Development Company, LLC
    Inventors: Steven P. Tanis, Timothy Parker, Robert C. Gadwood, James R. Zeller, Gerald D. Artman, III, Scott D. Larsen